LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the first quarter 2024. In a concurrent press release accompanying Agenus’ earnings announcement, a ...
Agenus Inc. Common Stock is estimated to report earnings on 11/05/2024. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual ...
quarterly report (10-q) august 08, 2024 sec filings thu, aug. 08 agenus, inc. (agen) q2 2024 earnings call transcript sa transcripts thu, aug. 08 5 comments agenus inc. 2024 q2 - results - earnings call presentation sa transcripts thu, aug. 08 agenus gaap eps of -$2.52 misses by ...
Twenty-four hours after the Scholar’s agreement, Gilead inked a deal with Agenus to receive exclusive worldwide rights to AGEN1423, and now we know that the drug targets -also- TGFß. If Gilead made its decision to choose Agenus’ anti-TGFß for oncology indications, rather than Schola...
per share). Earnings for Agenus are expected to grow in the coming year, from ($10.87) to ($10.73) per share. Agenus has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based off prior year's report ...
7:30 pm summary ratings financials earnings dividends valuation growth profitability momentum peers options charting profitability metrics profitability grade and underlying metrics agen profitability grade view ratings type grade agen sector median % diff. to sector agen 5y avg. % diff. to 5y avg. ...
Agenus Inc. (NASDAQ:AGEN) Q4 2021 Earnings Conference Call March 1, 2022 8:30 AM ETCompany ParticipantsDivya Vasudevan – Senior Director, Oncology Strategy...